A prodrome is an early set of signs, symptoms or other findings that occur before the onset of typical symptoms of a disease. Prodromal phases are well recognized in several neurological and inflammatory diseases, but the possibility of a prodrome in multiple sclerosis (MS) has received relatively little attention until the past few years. In this Perspective, we summarize what is currently known about the MS prodrome, including its possible duration, clinical features and potential biomarkers. We also consider what insights and lessons can be learned from knowledge of and research into the prodromal phases of other diseases. A better understanding of the MS prodrome could have profound clinical implications as it could enable earlier recognition of MS and earlier initiation of treatments that reduce relapse rates and long-term disability. Knowledge of the MS prodrome could also affect research into the causes of MS, and putative risk factors must be re-evaluated in light of the MS prodrome. We conclude by outlining the major knowledge gaps and propose future initiatives.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
European Journal of Nuclear Medicine and Molecular Imaging Open Access 07 December 2021
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162–173 (2018).
Wolfson, C. & Wolfson, D. B. The latent period of multiple sclerosis: a critical review. Epidemiology 4, 464–470 (1993).
Giovannoni, G. The neurodegenerative prodrome in multiple sclerosis. Lancet Neurol. 16, 413–414 (2017).
Hogg, T. et al. Mining healthcare data for markers of the multiple sclerosis prodrome. Mult. Scler. Relat. Disord. 25, 232–240 (2018).
Tremlett, H. & Marrie, R. A. The multiple sclerosis prodrome: emerging evidence, challenges, and opportunities. Mult. Scler. 27, 6–12 (2020).
Wijnands, J. M. A. et al. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurol. 16, 445–451 (2017).
Marrie, R. A. Mounting evidence for a multiple sclerosis prodrome. Nat. Rev. Neurol. 15, 689–690 (2019).
The Multiple Sclerosis International Federation. Atlas of MS 3rd Edition https://www.msif.org/wp-content/uploads/2020/10/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf (2020).
Wijnands, J. M. et al. Five years before multiple sclerosis onset: phenotyping the prodrome. Mult. Scler. 25, 1092–1101 (2019).
Wijnands, J. M. A. et al. Prodrome in relapsing-remitting and primary progressive multiple sclerosis. Eur. J. Neurol. 26, 1032–1036 (2019).
Yusuf, F. et al. Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome. Mult. Scler. 27, 290–302 (2020).
Zhao, Y. et al. Interrogation of the multiple sclerosis prodrome using high-dimensional health data. Neuroepidemiology 54, 140–147 (2020).
Yusuf, F. L. A. et al. A systematic review of morbidities suggestive of the multiple sclerosis prodrome. Expert Rev. Neurother. 20, 799–819 (2020).
Poser, C. M. et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13, 227–231 (1983).
Matthews, W. B. McAlpine’s Multiple Sclerosis 2nd edn (Churchill Livingstone, 1991).
Byatt, N., Rothschild, A. J., Riskind, P., Ionete, C. & Hunt, A. T. Relationships between multiple sclerosis and depression. J. Neuropsychiatry Clin. Neurosci. 23, 198–200 (2011).
Gout, O. et al. Prior suggestive symptoms in one-third of patients consulting for a “first” demyelinating event. J. Neurol. Neurosurg. Psychiatry 82, 323–325 (2011).
Sinay, V., Perez Akly, M., Zanga, G., Ciardi, C. & Racosta, J. M. School performance as a marker of cognitive decline prior to diagnosis of multiple sclerosis. Mult. Scler. 21, 945–952 (2015).
Disanto, G. et al. Prodromal symptoms of multiple sclerosis in primary care. Ann. Neurol. 83, 1162–1173 (2018).
Cortese, M. et al. Preclinical disease activity in multiple sclerosis: a prospective study of cognitive performance prior to first symptom. Ann. Neurol. 80, 616–624 (2016).
Marrie, R. A. et al. Increased mental health care use by mothers of children with multiple sclerosis. Neurology 94, e1040–e1050 (2020).
Marrie, R. A. et al. High rates of health care utilization in pediatric multiple sclerosis: a Canadian population-based study. PLoS ONE 14, e0218215 (2019).
Marrie, R. A. et al. Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. Epidemiol. Psychiatr. Sci. 28, 333–342 (2019).
Ponsonby, A. L. et al. Offspring number, pregnancy, and risk of a first clinical demyelinating event: the AusImmune Study. Neurology 78, 867–874 (2012).
Okuda, D. T. et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 72, 800–805 (2009).
Makhani, N. et al. Radiologically isolated syndrome in children: clinical and radiologic outcomes. Neurol. Neuroimmunol. Neuroinflamm 4, e395 (2017).
Granberg, T., Martola, J., Kristoffersen-Wiberg, M., Aspelin, P. & Fredrikson, S. Radiologically isolated syndrome — incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review. Mult. Scler. 19, 271–280 (2013).
Morris, Z. et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 339, b3016 (2009).
Kuhle, J. et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult. Scler. 21, 1013–1024 (2015).
Filippi, M. et al. Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurol. 17, 133–142 (2018).
Tintore, M. et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 138, 1863–1874 (2015).
Tintore, M. et al. Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. Neurology 87, 1368–1374 (2016).
Lebrun-Frenay, C. et al. Radiologically isolated syndrome: 10-year risk estimate of a clinical event. Ann. Neurol. 88, 407–417 (2020).
Kantarci, O. H. et al. Primary progressive multiple sclerosis evolving from radiologically isolated syndrome. Ann. Neurol. 79, 288–294 (2016).
Okuda, D. T. et al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS ONE 9, e90509 (2014).
Lebrun, C., Blanc, F., Brassat, D., Zephir, H. & de Seze, J. Cognitive function in radiologically isolated syndrome. Mult. Scler. 16, 919–925 (2010).
Amato, M. P. et al. Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology 78, 309–314 (2012).
Menascu, S. et al. Assessing cognitive performance in radiologically isolated syndrome. Mult. Scler. Relat. Disord. 32, 70–73 (2019).
Azevedo, C. J. et al. Early CNS neurodegeneration in radiologically isolated syndrome. Neurol. Neuroimmunol. Neuroinflamm. 2, e102 (2015).
George, I. C. et al. Cerebellar volume loss in radiologically isolated syndrome. Mult. Scler. 27, 130–133 (2019).
Alcaide-Leon, P. et al. Quantitative spinal cord MRI in radiologically isolated syndrome. Neurol. Neuroimmunol. Neuroinflamm. 5, e436 (2018).
Giorgio, A. et al. Cortical lesions in radiologically isolated syndrome. Neurology 77, 1896–1899 (2011).
Giorgio, A. et al. Appraisal of brain connectivity in radiologically isolated syndrome by modeling imaging measures. J. Neurosci. 35, 550–558 (2015).
Stromillo, M. L. et al. Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. Neurology 80, 2090–2094 (2013).
Bjornevik, K. et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol. 77, 58–64 (2020).
Matute-Blanch, C. et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain 141, 1085–1093 (2018).
Makhani, N. et al. Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. Mult. Scler. J. Exp. Transl Clin. 5, 2055217319836664 (2019).
Schafflick, D. et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat. Commun. 11, 247 (2020).
Beltrán, E. et al. Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis. J. Clin. Invest. 129, 4758–4768 (2019).
Simone, I. L. et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 59, 1922–1928 (2002).
Chitnis, T., Glanz, B., Jaffin, S. & Healy, B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult. Scler. 15, 627–631 (2009).
Jansen, P. R. et al. Incidental findings on brain imaging in the general pediatric population. N. Engl. J. Med. 377, 1593–1595 (2017).
Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69, 292–302 (2011).
Xia, Z. et al. Assessment of early evidence of multiple sclerosis in a prospective study of asymptomatic high-risk family members. JAMA Neurol. 74, 293–300 (2017).
De Stefano, N. et al. Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. Ann. Neurol. 59, 634–639 (2006).
Gabelic, T. et al. Prevalence of radiologically isolated syndrome and white matter signal abnormalities in healthy relatives of patients with multiple sclerosis. AJNR Am. J. Neuroradiol. 35, 106–112 (2014).
Berg, D. et al. MDS research criteria for prodromal Parkinson’s disease. Mov. Disord. 30, 1600–1611 (2015).
Heinzel, S. et al. Update of the MDS research criteria for prodromal Parkinson’s disease. Mov. Disord. 34, 1464–1470 (2019).
Postuma, R. B. Prodromal Parkinson disease: do we miss the signs? Nat. Rev. Neurol. 15, 437–438 (2019).
Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 280–292 (2011).
Mankia, K. & Emery, P. Preclinical rheumatoid arthritis: progress toward prevention. Arthritis Rheumatol. 68, 779–788 (2016).
Nielen, M. M. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50, 380–386 (2004).
van de Stadt, L. A., Witte, B. I., Bos, W. H. & van Schaardenburg, D. A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann. Rheum. Dis. 72, 1920–1926 (2013).
Greenblatt, H. K., Kim, H. A., Bettner, L. F. & Deane, K. D. Preclinical rheumatoid arthritis and rheumatoid arthritis prevention. Curr. Opin. Rheumatol. 32, 289–296 (2020).
van der Helm-van Mil, A. & Landewé, R. B. M. The earlier, the better or the worse? Towards accurate management of patients with arthralgia at risk for RA. Ann. Rheum. Dis. 79, 312–315 (2020).
Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526–1533 (2003).
Eriksson, C. et al. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res. Ther. 13, R30 (2011).
Melinder, C. et al. Physical fitness in adolescence and subsequent inflammatory bowel disease risk. Clin. Transl. Gastroenterol. 6, e121 (2015).
Turpin, W. et al. Increased intestinal permeability is associated with later development of Crohn’s disease. Gastroenterology 159, 2092–2100 (2020).
Porter, C. K., Cash, B. D., Pimentel, M., Akinseye, A. & Riddle, M. S. Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterol. 12, 55 (2012).
Runmarker, B. & Andersen, O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 118, 253–261 (1995).
McKay, K. A., Jahanfar, S., Duggan, T., Tkachuk, S. & Tremlett, H. Factors associated with onset, relapses or progression in multiple sclerosis: a systematic review. Neurotoxicology 61, 189–212 (2017).
Yong, H. Y., McKay, K. A., Daley, C. G. J. & Tremlett, H. Drug exposure and the risk of multiple sclerosis: a systematic review. Pharmacoepidemiol. Drug Saf. 27, 133–139 (2018).
Wijnands, J. M. A. & Tremlett, H. Concussion may not cause multiple sclerosis. Ann. Neurol. 82, 651–652 (2017).
Montgomery, S. et al. Reply to “concussion may not cause multiple sclerosis”. Ann. Neurol. 82, 652–653 (2017).
Montgomery, S. et al. Concussion in adolescence and risk of multiple sclerosis. Ann. Neurol. 82, 554–561 (2017).
Smith, K. A. et al. Hospital diagnosed pneumonia before age 20 years and multiple sclerosis risk. BMJ Neurol. Open 2, e000044 (2020).
Lucas, A. & Wolf, M. Vitamin D and health outcomes: then came the randomized clinical trials. JAMA 322, 1866–1868 (2019).
Yung, A. R. & Nelson, B. The ultra-high risk concept-a review. Can. J. Psychiatry 58, 5–12 (2013).
Liu, S.-Y., Chan, P. & Stoessl, A. J. The underlying mechanism of prodromal PD: insights from the parasympathetic nervous system and the olfactory system. Transl Neurodegener. 6, 4 (2017).
N.M. is funded by NIH/NINDS (grant number K23NS101099) and the Charles H. Hood Foundation. H.T. is the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis. Current research support has been received from the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, the Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation. In the past 5 years, she has received research support from the UK MS Trust and travel expenses to present at CME conferences from the Consortium of MS Centres (2018), the National MS Society (2016, 2018), ECTRIMS and ACTRIMS (2015, 2016, 2017, 2018, 2019, 2020), and the American Academy of Neurology (2015, 2016, 2019). Speaker honoraria are either declined or donated to an MS charity or to an unrestricted grant for use by H.T.’s research group.
Peer review information
Nature Reviews Neurology thanks M. Amato, T. Chitnis, G. Disanto and R. Dobson for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Makhani, N., Tremlett, H. The multiple sclerosis prodrome. Nat Rev Neurol 17, 515–521 (2021). https://doi.org/10.1038/s41582-021-00519-3
European Journal of Nuclear Medicine and Molecular Imaging (2022)
Nature Reviews Neurology (2022)